Iron Triangle Partners’s Heron Therapeutics HRTX Stock Holding History

Iron Triangle Partners’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-865,072	Closed	-$18.3M	–	31
2020 Q4	$18.3M	Buy	+865,072	New	+$15M	2.37%	18
2020 Q2	–	Sell	-500,000	Closed	-$5.87M	–	29
2020 Q1	$5.87M	Buy	+500,000	New	+$9.4M	2.27%	21

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Iron Triangle Partners's HRTX Position: Q1 2021 in Review

Iron Triangle Partners sold out of Heron Therapeutics (HRTX) in Q1 2021, closing a stake of 865,072 shares — an estimated $18.3M sold.

Iron Triangle Partners first reported a position in HRTX in Q1 2020 and held it in 2 quarters. The position peaked at $18.3M in Q4 2020. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2021.

Iron Triangle Partners reported no remaining Heron Therapeutics position as of Q1 2021 after selling out during the quarter.
Iron Triangle Partners sold 865,072 Heron Therapeutics shares in Q1 2021, an estimated $18.3M.
Iron Triangle Partners first reported a position in Heron Therapeutics in Q1 2020 and held it in 2 quarters.
Iron Triangle Partners's Heron Therapeutics position peaked at $18.3M in Q4 2020.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2021.

Based on Iron Triangle Partners's 13F filing for Q1 2021, filed 17 May 2021.